Metastasiertes kastrationsresistentes Prostatakarzinom = Metastatic castration-resistant prostate cancer : clinical data, new treatment options and therapy monitoring
Therapies currently available in Germany for metastatic castration-resistant prostate cancer (mCRPC) include docetaxel, cabazitaxel, abiraterone acetate, enzalutamide and radium-223, all of which offer a potential survival benefit that adds up in their sequential application to a significant overall...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | German |
| Published: |
13. Juli 2016
|
| In: |
Der Urologe
Year: 2016, Volume: 55, Issue: 9, Pages: 1206-1212 |
| DOI: | 10.1007/s00120-016-0176-4 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1007/s00120-016-0176-4
|
| Author Notes: | K. Miller, P. Albers, R. Eichenauer, G. Geiges, M.-O. Grimm, F. König, G. Mickisch, D. Pfister, C. Schwentner, H. Suttmann, S. Zastrow |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1685394191 | ||
| 003 | DE-627 | ||
| 005 | 20221117134955.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191212s2016 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00120-016-0176-4 |2 doi | |
| 035 | |a (DE-627)1685394191 | ||
| 035 | |a (DE-599)KXP1685394191 | ||
| 035 | |a (OCoLC)1341281575 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a ger | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Miller, Kurt |e VerfasserIn |0 (DE-588)1068875488 |0 (DE-627)820962805 |0 (DE-576)428234046 |4 aut | |
| 245 | 1 | 0 | |a Metastasiertes kastrationsresistentes Prostatakarzinom |b = Metastatic castration-resistant prostate cancer : clinical data, new treatment options and therapy monitoring |c K. Miller, P. Albers, R. Eichenauer, G. Geiges, M.-O. Grimm, F. König, G. Mickisch, D. Pfister, C. Schwentner, H. Suttmann, S. Zastrow |
| 246 | 3 | 1 | |a Metastatic castration-resistant prostate cancer |b clinical data, new treatment options and therapy monitoring |
| 264 | 1 | |c 13. Juli 2016 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.12.2019 | ||
| 520 | |a Therapies currently available in Germany for metastatic castration-resistant prostate cancer (mCRPC) include docetaxel, cabazitaxel, abiraterone acetate, enzalutamide and radium-223, all of which offer a potential survival benefit that adds up in their sequential application to a significant overall survival benefit. However, the optimal sequencing of these agents is still unclear. In the absence of evidence, treatment selection is based on the particular situation and on comorbid conditions of each individual patient. Furthermore, predictive markers to facilitate the selection of patients for a specific therapy or sequence of therapies remain an unmet need. However, with the recently discovered androgen receptor splice variant V7, which mediates (cross)resistance to or between abiraterone and enzalutamide, the first such marker has been identified. It is critical to monitor the response to treatments at prespecified intervals in order to optimize treatment sequencing so that the patient does not miss a valuable therapeutic window to receive alternative treatment that may prolong his life along with good symptom control and preservation of quality of life. | ||
| 650 | 4 | |a Abirateron | |
| 650 | 4 | |a Abiraterone | |
| 650 | 4 | |a Cabazitaxel | |
| 650 | 4 | |a Castration-resistant prostate cancer | |
| 650 | 4 | |a Docetaxel | |
| 650 | 4 | |a Enzalutamid | |
| 650 | 4 | |a Enzalutamide | |
| 650 | 4 | |a Kastrationsresistenz | |
| 700 | 1 | |a Mickisch, Gerald |e VerfasserIn |0 (DE-588)106861482X |0 (DE-627)820529710 |0 (DE-576)427941318 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Der Urologe |d [Berlin : Springer Medizin, 2005 |g 55(2016), 9, Seite 1206-1212 |h Online-Ressource |w (DE-627)101704192X |w (DE-600)2925337-8 |w (DE-576)501620842 |7 nnas |a Metastasiertes kastrationsresistentes Prostatakarzinom = Metastatic castration-resistant prostate cancer : clinical data, new treatment options and therapy monitoring |
| 773 | 1 | 8 | |g volume:55 |g year:2016 |g number:9 |g pages:1206-1212 |g extent:7 |a Metastasiertes kastrationsresistentes Prostatakarzinom = Metastatic castration-resistant prostate cancer : clinical data, new treatment options and therapy monitoring |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00120-016-0176-4 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191212 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 106861482X |a Mickisch, Gerald |m 106861482X:Mickisch, Gerald |d 60000 |d 63100 |e 60000PM106861482X |e 63100PM106861482X |k 0/60000/ |k 1/60000/63100/ |p 7 | ||
| 999 | |a KXP-PPN1685394191 |e 356410139X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 12.12.2019"],"recId":"1685394191","language":["ger"],"titleTranslated":[{"translated":"Metastatic castration-resistant prostate cancer"}],"person":[{"roleDisplay":"VerfasserIn","display":"Miller, Kurt","role":"aut","family":"Miller","given":"Kurt"},{"role":"aut","display":"Mickisch, Gerald","roleDisplay":"VerfasserIn","given":"Gerald","family":"Mickisch"}],"title":[{"title_sort":"Metastasiertes kastrationsresistentes Prostatakarzinom","subtitle":" = Metastatic castration-resistant prostate cancer : clinical data, new treatment options and therapy monitoring","title":"Metastasiertes kastrationsresistentes Prostatakarzinom"}],"physDesc":[{"extent":"7 S."}],"relHost":[{"title":[{"title_sort":"Urologe","title":"Der Urologe"}],"part":{"text":"55(2016), 9, Seite 1206-1212","volume":"55","extent":"7","year":"2016","issue":"9","pages":"1206-1212"},"pubHistory":["Volume 44, issue 7 (July 2005)-volume 61, issue 5 (May 2022)"],"recId":"101704192X","corporate":[{"roleDisplay":"Herausgebendes Organ","display":"Deutsche Gesellschaft für Urologie","role":"isb"}],"language":["ger"],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Metastasiertes kastrationsresistentes Prostatakarzinom = Metastatic castration-resistant prostate cancer : clinical data, new treatment options and therapy monitoringDer Urologe","note":["Gesehen am 05.07.2022"],"id":{"zdb":["2925337-8"],"eki":["101704192X"]},"origin":[{"publisher":"Springer Medizin","dateIssuedDisp":"[2005-2022]","publisherPlace":"[Berlin ; Heidelberg ; New York]"}],"name":{"displayForm":["Deutsche Gesellschaft für Urologie"]},"physDesc":[{"extent":"Online-Ressource"}]}],"name":{"displayForm":["K. Miller, P. Albers, R. Eichenauer, G. Geiges, M.-O. Grimm, F. König, G. Mickisch, D. Pfister, C. Schwentner, H. Suttmann, S. Zastrow"]},"origin":[{"dateIssuedDisp":"13. Juli 2016","dateIssuedKey":"2016"}],"id":{"doi":["10.1007/s00120-016-0176-4"],"eki":["1685394191"]}} | ||
| SRT | |a MILLERKURTMETASTASIE1320 | ||